Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2448610 | 0.88 | PSIP1 (0.56) | PSIP1KEAP1NFE2L2ALDH1A1CYP2C9 | |
| SCHEMBL16485594 | 0.86 | PSIP1 (0.46) | PSIP1KEAP1NFE2L2ALDH1A1CYP3A4 | |
| SCHEMBL13917416 | 0.81 | PLCG1 (0.52) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL576918 | 0.81 | KEAP1 (0.63) | PSIP1KEAP1NFE2L2ALDH1A1CYP3A4 | |
| SCHEMBL10629823 | 0.81 | PSIP1 (0.61) | PSIP1KEAP1NFE2L2ALDH1A1CYP3A4 | |
| SCHEMBL28732982 | 0.81 | HDAC1 (0.50) | PSIP1KEAP1NFE2L2ALDH1A1CYP3A4 | |
| SCHEMBL10626503 | 0.79 | HDAC1 (0.65) | PSIP1KEAP1NFE2L2ALDH1A1CYP3A4 | |
| SCHEMBL27496055 | 0.79 | MAPK1 (0.44) | PSIP1KEAP1NFE2L2ALDH1A1CYP3A4 | |
| Isopropylamine SCHEMBL10862241 | 0.78 | PSIP1 (0.53) | PSIP1KEAP1NFE2L2ALDH1A1CYP3A4 | |
| SCHEMBL777886 | 0.78 | PSIP1 (0.64) | PSIP1KEAP1NFE2L2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-1498417-A1 | Heterocyclic amide derivatives | Pfizer Products Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004039375-A1 | METHODS OF USING CCR1 ANTAGONISTS AS IMMUNOMODULATORY AGENTS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | PFIZER INC | 2004-05-06 | — | — | US | disclosed |
| US-6689886-B2 | TREATMENT OF INFLAMMATION AND OTHER IMMUNE DISORDERS | PFIZER INC. | 2004-02-10 | — | — | US | disclosed |
| US-20030204086-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2003-10-30 | — | — | US | disclosed |
| US-6548671-B2 | Treating autoimmune diseases, inflammatory conditions, allergies, infections, viral diseases, bronchitis, transplant tissue rejection, atherosclerosis, restenosis, HIV infectivity, and granulomatous | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| EP-1252154-A1 | HETEROCYCLIC AMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | BROWN MATTHEW F (US) | 2002-09-19 | — | — | US | disclosed |
| WO-2001057023-A1 | HETEROCYCLIC AMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204086-A1 | Novel heterocyclic amide derivatives | HAX1, ARG1, CXCR2 | PSIP1 4173/4885KEAP1 807/4885NFE2L2 689/4885 |
| US-20040087571-A1 | Methods of using CCR1 antagonists as immunomodulatory agents | CCR1, CCR3, CCRL2 | PSIP1 4736/4885KEAP1 1500/4885NFE2L2 3977/4885 |
| US-20020132810-A1 | Novel heterocyclic amide derivatives | ARG1, IL4, ARG2 | PSIP1 3358/4885KEAP1 1004/4885NFE2L2 893/4885 |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | PSIP1 1161/4885KEAP1 1914/4885NFE2L2 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.